Logo Image
News|Articles|May 1, 2010

First-time generic approvals May 2010

Generic drugs approved by FDA (through April 2010): Losartan potassium tablets in 25-mg, 50-mg, and 100-mg, Losartan potassium and hydrochlorothiazide tablets in 50 mg/12.5 mg, 100 mg/12.5-mg, and 100 mg/25 mg, Hydromorphone hydrochloride injection, Mesna injection

Losartan potassium tablets in 25-mg, 50-mg, and 100-mg strengths (equiv to Cozaar)

TEVA PHARMACEUTICALS

Losartan potassium and hydrochlorothiazide tablets in 50 mg/12.5 mg, 100 mg/12.5-mg, and 100 mg/25 mg strengths (equiv to Hyzaar)

Hydromorphone hydrochloride injection 10 mg/mL in 1-, 5-, and 50-mL doses (equiv to Dilaudid-HP 10 mg/mL injection)

AKORN

Mesna injection in 1 mg per 10 mL multi-dose vials (equiv to Mesnex)

STRIDES ARCOLAB

Related Content

Latest CME

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment
Video

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

Jonathan Goldman, MD; Sanja Dacic, MD, PhD; Deborah Doroshow, MD, PhD; Anne S. Tsao, MD, MBA

View more
27th Annual International Lung Cancer Congress®
Video

27th Annual International Lung Cancer Congress®

Roy S. Herbst, MD, PhD; Sandip Patel, MD, FASCO; Heather A. Wakelee, MD, FASCO

View more
Tennessee Oncology Practice Society
Virtual Event

Tennessee Oncology Practice Society

2 Sessions are Available!

View more
20th Annual New York Lung Cancers Symposium®
Video

20th Annual New York Lung Cancers Symposium®

Balazs Halmos, MD, MS; Jamie Chaft, MD

View more
Hot Seat: Converging Lines in the Management of RAS-Altered Cancers
Video

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Shubham Pant, MD, MBBS; Alison Schram, MD; Helena Yu, MD

View more
From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS
Video

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD

View more
Tumor Board: Translating HER2 and TROP2 Innovations to Transform NSCLC Care
Video

Tumor Board: Translating HER2 and TROP2 Innovations to Transform NSCLC Care

Jacob Sands, MD; Marina Chiara Garassino, MD; Eric K. Singhi, MD

View more
Shifting the Paradigm in Small Cell Lung Cancer: Targeting Tumor Biology to Transform Patient Outcomes
Video

Shifting the Paradigm in Small Cell Lung Cancer: Targeting Tumor Biology to Transform Patient Outcomes

Charles M. Rudin, MD, PhD; Alex A. Adjei, MD, PhD; Millie Das, MD

View more